Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2009

View Archived Issues

4SC commences phase II 4SC-201 trial in hepatocellular carcinoma

Sitaxsentan treatment has multiple benefits in chronic kidney disease

Pfizer develops novel irreversible and reversible SARS 3CL protease inhibitors

Tumor hypoxia marker [18F]HX4 safe in phase I trial, phase II study planned

Novavax reports preclinical results from ferret study of H1N1 influenza VLP vaccine

Lpath completes enrollment in phase I study of iSonep in wet AMD

Roche reports results for first half 2009

GlaxoSmithKline claims tricyclic nitrogen-containing compounds as antibacterials

Array BioPharma describes Akt protein kinase inhibitors for cancer

Cathepsin K inhibitors identified at Amura for treating bone disorders

Solvay discloses bifeprunox derivatives for PD and other CNS-related disorders

LXR ligands for a variety of potential applications described by Wyeth

Abbott discloses new calpain inhibitors for neurological and other disorders

Focus of gamma-secretase inhibitor PF-3084014 shifts to cancer

Bristol-Myers Squibb identifies potent corticotropin-releasing factor-1 receptor antagonist

Light Sciences Oncology treats patients in phase II Aptocine trial in BPH

Peplin completes enrollment in final phase III ingenol mebutate trial in AK

COTI-2 plus Doxil superior to Doxil alone in animal ovarian cancer model

Amira submits IND for AM-461

Ablynx reports phase I results for subcutaneous administration of ALX-0681

Forest reports phase IIb results for oglemilast in COPD

Pfizer targets the type 1 glycine transporter with PF-3463275 for schizophrenia

Severe lung damage linked to long-term occupational nanoparticle exposure

InterMune and Roche initiate dosing in phase IIb clinical trial of ITMN-191

Gentium reports results from phase III defibrotide trial for sVOD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...